dc.contributor.author | Colomba, E | |
dc.contributor.author | Le Teuff, G | |
dc.contributor.author | Eisen, T | |
dc.contributor.author | Stewart, GD | |
dc.contributor.author | Fife, K | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Biondo, A | |
dc.contributor.author | Pickering, L | |
dc.contributor.author | Srinivasan, A | |
dc.contributor.author | Boyle, H | |
dc.contributor.author | Derosa, L | |
dc.contributor.author | Sternberg, CN | |
dc.contributor.author | Recine, F | |
dc.contributor.author | Ralph, C | |
dc.contributor.author | Saldana, C | |
dc.contributor.author | Barthelemy, P | |
dc.contributor.author | Bernhard, JC | |
dc.contributor.author | Gurney, H | |
dc.contributor.author | Verhoest, G | |
dc.contributor.author | Vauleon, E | |
dc.contributor.author | Bigot, P | |
dc.contributor.author | Berger, J | |
dc.contributor.author | Pfister, C | |
dc.contributor.author | Gravis, G | |
dc.contributor.author | Rodier, J-M | |
dc.contributor.author | Culine, S | |
dc.contributor.author | Caty, A | |
dc.contributor.author | Rolland, F | |
dc.contributor.author | Priou, F | |
dc.contributor.author | Escudier, B | |
dc.contributor.author | Albiges, L | |
dc.date.accessioned | 2018-02-20T12:00:24Z | |
dc.date.issued | 2017-07 | |
dc.identifier | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000403329300008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9 | |
dc.identifier.citation | EUROPEAN JOURNAL OF CANCER, 2017, 80 pp. 55 - 62 | |
dc.identifier.issn | 0959-8049 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1398 | |
dc.identifier.eissn | 1879-0852 | |
dc.identifier.doi | 10.1016/j.ejca.2017.03.011 | |
dc.format.extent | 55 - 62 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.subject | Non-clear cell RCC | |
dc.subject | Chromophobe RCC | |
dc.subject | Metastatic | |
dc.subject | Anti-angiogenic | |
dc.subject | VEGF | |
dc.subject | mTOR | |
dc.title | Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1016/j.ejca.2017.03.011 | |
rioxxterms.licenseref.startdate | 2017-07 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | EUROPEAN JOURNAL OF CANCER | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 80 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Melanoma and Kidney Cancer | en_US |
dc.contributor.icrauthor | Larkin, James | en |
dc.contributor.icrauthor | Marsden, | en |